Abstract:Selective and controlled expansion of endogenous β-cells has been pursued as a potential therapy for diabetes. Ideally, such therapies would preserve feedback control of β-cell proliferation to avoid excessive β-cell expansion and an increased risk of hypoglycemia. Here, we identified a regulator of β-cell proliferation whose inactivation results in controlled β-cell expansion: the protein deacetylase Sirtuin 2 (SIRT2). deletion in β-cells of mice increased β-cell proliferation during hyperglycemia with little effect in homeostatic conditions, indicating preservation of feedback control of β-cell mass. SIRT2 restrains proliferation of human islet β-cells cultured in glucose concentrations above the glycemic set point, demonstrating conserved SIRT2 function. Analysis of acetylated proteins in islets treated with a SIRT2 inhibitor revealed that SIRT2 deacetylates enzymes involved in oxidative phosphorylation, dampening the adaptive increase in oxygen consumption during hyperglycemia. At the transcriptomic level, inactivation has context-dependent effects on β-cells, with controlling how β-cells interpret hyperglycemia as a stress. Finally, we provide proof-of-principle that systemic administration of a GLP1-coupled -targeting antisense oligonucleotide achieves β-cell selective inactivation and stimulates β-cell proliferation under hyperglycemic conditions. Overall, these studies identify a therapeutic strategy for increasing β-cell mass in diabetes without circumventing feedback control of β-cell proliferation.

What problem does this paper attempt to address?

The problem that this paper attempts to solve is how to achieve the proliferation of β - cells (islet β - cells) by controlling specific proteins in order to treat diabetes. Specifically, the researchers focused on the role of Sirtuin 2 (SIRT2), a protein deacetylase, in β - cell proliferation. They found that under hyperglycemic conditions, the inactivation of SIRT2 can promote the proliferation of β - cells while maintaining the feedback control of β - cell proliferation, avoiding the risks caused by excessive proliferation, such as hypoglycemia. This finding provides a theoretical basis for the development of new diabetes treatment methods, especially those aiming to increase the number of β - cells without bypassing the feedback regulation mechanism. The key points of the paper include: - **The role of SIRT2**: SIRT2 is a protein that inhibits proliferation in β - cells, and its activity is related to the intracellular NAD+ level. Under hyperglycemic conditions, the activity of SIRT2 is inhibited, thus allowing β - cells to proliferate. - **Experimental verification**: Through gene knockout and pharmacological methods, the researchers confirmed that the deletion or inhibition of SIRT2 can specifically enhance the proliferation of β - cells under hyperglycemic conditions, while having a relatively small impact on β - cells under normoglycemic conditions. - **Mechanism exploration**: SIRT2 regulates the metabolic state of β - cells by deacetylating enzymes involved in oxidative phosphorylation. The inactivation of SIRT2 leads to the activation of these enzymes, which in turn affects the adaptive metabolic changes of β - cells. - **Transcriptome analysis**: Using single - cell RNA sequencing technology, the researchers observed that insulin resistance and hyperglycemia caused by S961 can change the transcriptional state of β - cells, and the deletion of SIRT2 further affects the changes of these states, especially increasing the proportion of β - cell subpopulations related to oxidative phosphorylation and ROS. Overall, this study provides a potential treatment strategy, that is, by selectively inhibiting SIRT2 to increase the number of β - cells in diabetic patients while retaining the natural feedback control mechanism of β - cell proliferation, which may contribute to a safer and more effective treatment of diabetes.

Metabolic control of adaptive β-cell proliferation by the protein deacetylase SIRT2

Successful Β Cells Islet Regeneration in Streptozotocin-Induced Diabetic Baboons Using Ultrasound-Targeted Microbubble Gene Therapy with Cyclind2/cdk4/glp1

Targeted Pharmacological Therapy Restores Beta-Cell Function For Diabetes Remission

Inhibition of de novo ceramide synthesis by Sirtuin-1 improves beta-cell function and glucose metabolism in type 2 diabetes

SIRT2 ablation inhibits glucose-stimulated insulin secretion through decreasing glycolytic flux

E2F1 transcription factor mediates a link between fat and islets to promote β cell proliferation in response to acute insulin resistance

Mitofusin2 Promotes Β Cell Maturation from Mouse Embryonic Stem Cells Via Sirt3/Idh2 Activation

BACE2 suppression promotes β-cell survival and function in a model of type 2 diabetes induced by human islet amyloid polypeptide overexpression

Human Expandable Pancreatic Progenitor–derived Β Cells Ameliorate Diabetes

Sirtinol Promotes PEPCK1 Degradation and Inhibits Gluconeogenesis by Inhibiting Deacetylase SIRT2.

Conditional ablation of Gsk-3β in islet beta cells results in expanded mass and resistance to fat feeding-induced diabetes in mice

Sphingosine‑1‑phosphate Induces Islet Β‑cell Proliferation and Decreases Cell Apoptosis in High‑fat Diet/streptozotocin Diabetic Mice

Inhibition of PHLPP1/2 phosphatases rescues pancreatic β-cells in diabetes

Deletion of Pancreatic Β‐cell Adenosine Kinase Improves Glucose Homeostasis in Young Mice and Ameliorates Streptozotocin‐induced Hyperglycaemia

A Novel SIRT1 Activator E6155 Improves Insulin Sensitivity in Type 2 Diabetic KKAy Mice

Inhibition of DYRK1A Stimulates Human β-Cell Proliferation

Pancreas-Specific Sirt1-Deficiency in Mice Compromises Beta-Cell Function Without Development of Hyperglycemia.

Tead1 reciprocally regulates adult β-cell proliferation and function to maintain glucose homeostasis

Activation of Nrf2 Is Required for Normal and ChREBPα-Augmented Glucose-Stimulated β-Cell Proliferation

Targeting the pancreatic β-cell to treat diabetes

Inhibition of TBK1/IKKε Promotes Regeneration of Pancreatic β-cells